| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Regular Articles |
From the Departments of Pathology*
and InternalMedicine,
Division of Hematology and Oncology,and the Comprehensive Cancer Center,
University of Michigan, Ann Arbor, Michigan
The most important factor in predicting outcome in patients with early breast cancer is the stage of the disease. There is no robust marker capable of identifying invasive carcinomas that despite their small size have a high metastatic potential, and that would benefit from more aggressive treatment. RhoC-GTPase is a member of the Ras-superfamily and is involved in cell polarity and motility. We hypothesized that RhoC expression would be a good marker to identify breast cancer patients with high risk of developing metastases, and that it would be a prognostic marker useful in the clinic. We developed a specific anti-RhoC antibody and studied archival breast tissues that comprise a broad spectrum of breast disease. One hundred eighty-two specimens from 164 patients were used. Immunohistochemistry was performed on formalin-fixed tissues. Staining intensity was graded 0 to 3+ (0 to 1+ was considered negative and 2 to 3+ was considered positive). RhoC was not expressed in any of the normal, fibrocystic changes, atypical hyperplasia, or ductal carcinoma in situ, but was expressed in 36 of 118 invasive carcinomas and strongly correlated with tumor stage (P = 0.01). RhoC had high specificity (88%) in detecting invasive carcinomas with metastatic potential. Of the invasive carcinomas smaller than 1 cm, RhoC was highly specific in detecting tumors that developed metastases. RhoC expression was associated with negative progesterone receptor and HER-2/neu overexpression. We characterized RhoC expression in human breast tissues. RhoC is specifically expressed in invasive breast carcinomas capable of metastasizing, and it may be clinically useful in patients with tumors smaller than 1 cm to guide treatment.
This article has been cited by other articles:
 |
|
 |
|
  M. Islam, G. Lin, J. C. Brenner, Q. Pan, S. D. Merajver, Y. Hou, P. Kumar, and T. N. Teknos RhoC Expression and Head and Neck Cancer Metastasis Mol. Cancer Res., November 1, 2009; 7(11): 1771 - 1780. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. N. Khan, M. A. Gorin, D. Rosenthal, Q. Pan, L. W. Bao, Z. F. Wu, R. A. Newman, A. D. Pawlus, P. Yang, E. P. Lansky, et al. Pomegranate Fruit Extract Impairs Invasion and Motility in Human Breast Cancer Integr Cancer Ther, September 1, 2009; 8(3): 242 - 253. [Abstract] [PDF]
|
|
|
|
 |
|
 J. A. Sparano, S. Moulder, A. Kazi, D. Coppola, A. Negassa, L. Vahdat, T. Li, C. Pellegrino, S. Fineberg, P. Munster, et al. Phase II Trial of Tipifarnib plus Neoadjuvant Doxorubicin-Cyclophosphamide in Patients with Clinical Stage IIB-IIIC Breast Cancer Clin. Cancer Res., April 15, 2009; 15(8): 2942 - 2948. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Fang, L.-B. Luo, Y.-M. Tao, F. Wu, and L.-Y. Yang Decreased Expression of Inhibitor of Growth 4 Correlated with Poor Prognosis of Hepatocellular Carcinoma Cancer Epidemiol. Biomarkers Prev., February 1, 2009; 18(2): 409 - 416. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Q. Pan, L. W. Bao, T. N. Teknos, and S. D. Merajver Targeted Disruption of Protein Kinase C{varepsilon} Reduces Cell Invasion and Motility through Inactivation of RhoA and RhoC GTPases in Head and Neck Squamous Cell Carcinoma Cancer Res., October 1, 2006; 66(19): 9379 - 9384. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Sparano, S. Moulder, A. Kazi, L. Vahdat, T. Li, C. Pellegrino, P. Munster, M. Malafa, D. Lee, S. Hoschander, et al. Targeted Inhibition of Farnesyltransferase in Locally Advanced Breast Cancer: A Phase I and II Trial of Tipifarnib Plus Dose-Dense Doxorubicin and Cyclophosphamide J. Clin. Oncol., July 1, 2006; 24(19): 3013 - 3018. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. R. Croft and M. F. Olson The Rho GTPase Effector ROCK Regulates Cyclin A, Cyclin D1, and p27Kip1 Levels by Distinct Mechanisms Mol. Cell. Biol., June 15, 2006; 26(12): 4612 - 4627. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. J. Fiordalisi, P. J. Keller, and A. D. Cox PRL tyrosine phosphatases regulate rho family GTPases to promote invasion and motility. Cancer Res., March 15, 2006; 66(6): 3153 - 3161. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Krop, A. Marz, H. Carlsson, X. Li, N. Bloushtain-Qimron, M. Hu, R. Gelman, M. S. Sabel, S. Schnitt, S. Ramaswamy, et al. A Putative Role for Psoriasin in Breast Tumor Progression Cancer Res., December 15, 2005; 65(24): 11326 - 11334. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Hakuma, I. Kinoshita, Y. Shimizu, K. Yamazaki, K. Yoshida, M. Nishimura, and H. Dosaka-Akita E1AF/PEA3 Activates the Rho/Rho-Associated Kinase Pathway to Increase the Malignancy Potential of Non-Small-Cell Lung Cancer Cells Cancer Res., December 1, 2005; 65(23): 10776 - 10782. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Q. Pan, L. W. Bao, C. G. Kleer, M. S. Sabel, K. A. Griffith, T. N. Teknos, and S. D. Merajver Protein Kinase C{varepsilon} Is a Predictive Biomarker of Aggressive Breast Cancer and a Validated Target for RNA Interference Anticancer Therapy Cancer Res., September 15, 2005; 65(18): 8366 - 8371. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W-B Zhong, Y-C Liang, C-Y Wang, T-C Chang, and W-S Lee Lovastatin suppresses invasiveness of anaplastic thyroid cancer cells by inhibiting Rho geranylgeranylation and RhoA/ROCK signaling Endocr. Relat. Cancer, September 1, 2005; 12(3): 615 - 629. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. K. Witkiewicz, S. Varambally, R. Shen, R. Mehra, M. S. Sabel, D. Ghosh, A. M. Chinnaiyan, M. A. Rubin, and C. G. Kleer {alpha}-Methylacyl-CoA Racemase Protein Expression Is Associated with the Degree of Differentiation in Breast Cancer Using Quantitative Image Analysis Cancer Epidemiol. Biomarkers Prev., June 1, 2005; 14(6): 1418 - 1423. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-Y. Lang, H. Chen, J. Zhou, Y.-X. Zhang, X.-W. Zhang, M.-H. Li, L.-P. Lin, J.-S. Zhang, M. P. Waalkes, and J. Ding Antimetastatic Effect of Salvicine on Human Breast Cancer MDA-MB-435 Orthotopic Xenograft Is Closely Related to Rho-Dependent Pathway Clin. Cancer Res., May 1, 2005; 11(9): 3455 - 3464. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. M. Jacobsen, S. A. Schittone, J. K. Richer, and K. B. Horwitz Progesterone-Independent Effects of Human Progesterone Receptors (PRs) in Estrogen Receptor-Positive Breast Cancer: PR Isoform-Specific Gene Regulation and Tumor Biology Mol. Endocrinol., March 1, 2005; 19(3): 574 - 587. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. R. Croft, E. Sahai, G. Mavria, S. Li, J. Tsai, W. M. F. Lee, C. J. Marshall, and M. F. Olson Conditional ROCK Activation In vivo Induces Tumor Cell Dissemination and Angiogenesis Cancer Res., December 15, 2004; 64(24): 8994 - 9001. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. B. Geigl, S. Langer, S. Barwisch, K. Pfleghaar, G. Lederer, and M. R. Speicher Analysis of Gene Expression Patterns and Chromosomal Changes Associated with Aging Cancer Res., December 1, 2004; 64(23): 8550 - 8557. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. J. Simpson, A. S. Dugan, and A. M. Mercurio Functional Analysis of the Contribution of RhoA and RhoC GTPases to Invasive Breast Carcinoma Cancer Res., December 1, 2004; 64(23): 8694 - 8701. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M Lacroix, R-A Toillon, and G Leclercq Stable 'portrait' of breast tumors during progression: data from biology, pathology and genetics Endocr. Relat. Cancer, September 1, 2004; 11(3): 497 - 522. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Vasiliev, T. Omelchenko, I. M. Gelfand, H. H. Feder, and E. M. Bonder From the Cover: Rho overexpression leads to mitosis-associated detachment of cells from epithelial sheets: A link to the mechanism of cancer dissemination PNAS, August 24, 2004; 101(34): 12526 - 12530. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Mazieres, T. Antonia, G. Daste, C. Muro-Cacho, D. Berchery, V. Tillement, A. Pradines, S. Sebti, and G. Favre Loss of RhoB Expression in Human Lung Cancer Progression Clin. Cancer Res., April 15, 2004; 10(8): 2742 - 2750. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Ikoma, T. Takahashi, S. Nagano, Y.-M. Li, Y. Ohno, K. Ando, T. Fujiwara, H. Fujiwara, and K.-i. Kosai A Definitive Role of RhoC in Metastasis of Orthotopic Lung Cancer in Mice Clin. Cancer Res., February 1, 2004; 10(3): 1192 - 1200. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. G. Jiang, G. Watkins, J. Lane, G. H. Cunnick, A. Douglas-Jones, K. Mokbel, and R. E. Mansel Prognostic Value of Rho GTPases and Rho Guanine Nucleotide Dissociation Inhibitors in Human Breast Cancers Clin. Cancer Res., December 15, 2003; 9(17): 6432 - 6440. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Shikada, I. Yoshino, T. Okamoto, S. Fukuyama, T. Kameyama, and Y. Maehara Higher Expression of RhoC Is Related to Invasiveness in Non-Small Cell Lung Carcinoma Clin. Cancer Res., November 1, 2003; 9(14): 5282 - 5286. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Gariboldi, M. Spinola, S. Milani, C. Pignatiello, K. Kadota, H. Bono, Y. Hayashizaki, T. A. Dragani, and Y. Okazaki Gene expression profile of normal lungs predicts genetic predisposition to lung cancer in mice Carcinogenesis, November 1, 2003; 24(11): 1819 - 1826. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. A. Collisson, C. Kleer, M. Wu, A. De, S. S. Gambhir, S. D. Merajver, and M. S. Kolodney Atorvastatin prevents RhoC isoprenylation, invasion, and metastasis in human melanoma cells Mol. Cancer Ther., October 1, 2003; 2(10): 941 - 948. [Abstract] [Full Text]
|
|
|
|
 |
|
 S. F. Doisneau-Sixou, P. Cestac, S. Chouini, J. S. Carroll, A. D. Hamilton, S. M. Sebti, M. Poirot, P. Balaguer, J.-C. Faye, R. L. Sutherland, et al. Contrasting Effects of Prenyltransferase Inhibitors on Estrogen-Dependent Cell Cycle Progression and Estrogen Receptor-Mediated Transcriptional Activity in MCF-7 Cells Endocrinology, March 1, 2003; 144(3): 989 - 998. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. T. Arthur, S. M. Ellerbroek, C. J. Der, K. Burridge, and K. Wennerberg XPLN, a Guanine Nucleotide Exchange Factor for RhoA and RhoB, But Not RhoC J. Biol. Chem., November 1, 2002; 277(45): 42964 - 42972. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. L. van Golen, L. Bao, M. M. DiVito, Z. Wu, G. C. Prendergast, and S. D. Merajver Reversion of RhoC GTPase-induced Inflammatory Breast Cancer Phenotype by Treatment with a Farnesyl Transferase Inhibitor Mol. Cancer Ther., June 1, 2002; 1(8): 575 - 583. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
